Abstracts Archive - Page 2305 of 2425 - ACR Meeting Abstracts

Abstract Number: 1777 • 2012 ACR/ARHP Annual Meeting
The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells
Martin Hahne¹, Cindy Strehl¹, Manuela Jakstadt¹, Paula Hoff¹, Timo Gaber¹, Gerd Burmester¹ and Frank Buttgereit², ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Hypoxia and angiogenesis are features of inflamed and injured tissues. The transcription factors Hypoxia inducible factor (HIF)-1 and (HIF)-2 control cellular metabolic response to…
Abstract Number: 1737 • 2012 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome
Rodrigo Cartin-Ceba¹, Tobias Peikert², Karina Keogh², Steven R. Ytterberg³, Aneel Ashrani⁴ and Ulrich Specks², ¹Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴Hematology, Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an uncommon but severe complication of primary antiphospholipid syndrome (APS). The available literature is limited to very few case…
Abstract Number: 1738 • 2012 ACR/ARHP Annual Meeting
Myocardial Dysfunction and Valvulopathy Worsens with Time in Patients with Antiphospholipid Syndrome: A 10-Year Follow-up Study
MG Tektonidou¹, CF Kampolis², I. Moyssakis³, GE Tzelepis², Haralampos M. Moutsopoulos² and P. Vlachoyiannopoulos², ¹First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece, ²Department of Pathophysiology, University of Athens Medical School, Laiko Hospital, Athens, Greece, ³Department of Cardiology, Laiko Hospital, Athens, Greece
Background/Purpose: Valvular disease represents the most common cardiac manifestation among patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) positive for antiphospholipid antibodies (aPL).…
Abstract Number: 1740 • 2012 ACR/ARHP Annual Meeting
Impairment of Quality of Life in Patients with Antiphospholipid Syndrome
Stephane Zuily¹, Francis Guillemin², Veronique Regnault³, Pierre Kaminsky⁴, Patrick Mismetti⁵, Jacques Ninet⁶, Nicolas Baillet⁷, Nadine Magy-Bertrand⁸, Bernard Lorcerie⁹, Jean-Louis Pasquali¹⁰, Thomas Lecompte¹¹, Anne-Christine Rat¹² and Denis Wahl¹³, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, Orphan disease Unit, Nancy, France, ⁵CHU Saint-Etienne, Unité de Pharmacologie Clinique, Groupe de Recherche sur la Thrombose (EA 3065), Saint Etienne, France, ⁶Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁷Hôpitaux civils de Colmar, Service de Médecine interne, Colmar, France, ⁸CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁹Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁰Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ¹¹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹²Université de Lorraine, INSERM, CIC-EC CIE6, Rheumatology, Epidemiology, Nancy, France, ¹³Nancy University Hospital and INSERM U961, Vascular medicine division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France
Background/Purpose : Quality of life (QoL) is an important outcome in clinical care especially in patients with chronic disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 1741 • 2012 ACR/ARHP Annual Meeting
Suppression of Glomerulonephritis in NZB/W F1 Mice by a Selective Inhibitor of Bruton’s Tyrosine Kinase (RN486)
Paola Mina-Osorio¹, Jacob LaStant¹, Natalie Keirstead¹, Toni Whittard¹, Stella Stefanova¹, Alka Patel¹, Jennifer Postelnek¹, John Woods², Soo Min², Yong Kim¹, Julie Demartino², Satwant Narula³ and Daigen Xu¹, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, ³Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ
Background/Purpose: Bruton tyrosine kinase (Btk) is a Tec family kinase that participates in B cell receptor (BCR), Toll-like Receptor (TLR) and chemokine receptor signaling. It…
Abstract Number: 1742 • 2012 ACR/ARHP Annual Meeting
A Novel Murine Model of B Cell-Mediated Proteinuria Suggests Cytokines Mediate Podocyte Injury
Alfred Kim¹ and Andrey S. Shaw², ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: B cell depletion therapies have been efficacious in several glomerulopathies. The contributions of B cells to proteinuria and foot process effacement remain unknown. The…
Abstract Number: 1743 • 2012 ACR/ARHP Annual Meeting
IL-5-Induced FasL⁺ Regulatory B Cells Are Inhibited by IL-4 and Cyclosporine
Matthew W. Klinker¹, Brian R. Alzua¹, Tamra J. Reed², David A. Fox³ and Steven K. Lundy⁴, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology/Int Medicine, Univ of Michigan Med Ctr, Ann Arbor, MI, ⁴Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: We previously identified a subset of regulatory B cells that express the apoptosis-inducing molecule Fas ligand (FasL), and reported that these B cells were…
Abstract Number: 1744 • 2012 ACR/ARHP Annual Meeting
Regulatory B Cells Supress the Progression of Fatal Autoimmunity in Lupus-Prone Mice
Yuriy Baglaenko¹, Nan-Hua Chang², Evelyn Pau³ and Joan E. Wither⁴, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disorder characterized by the production of anti-nuclear antibodies (ANA) which form immune complexes and promote…
Abstract Number: 1745 • 2012 ACR/ARHP Annual Meeting
Amelioration of Experimental Autoimmune Arthritis by Adoptive Transfer of Foxp3-Expressing Regulatory B Cells Is Associated with the Regulatory T Cell/T helper 17 cell Balance
Young Ok Jung¹, Yu Jung Heo², Mi Kyung Park³, Mi-La Cho⁴, Seung Ki Kwok⁵, Ji Hyeon Ju², Kyung Su PARK², Sung Hwan PARK², Ho Youn Kim² and Jun-Ki Min⁶, ¹Internal Medicine Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ²Catholic University, Seoul, South Korea, ³Rheumatism Research Center (RhRC), The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ⁵The Catholic University, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expression is thought to be T cell-restricted.…
Abstract Number: 1746 • 2012 ACR/ARHP Annual Meeting
Semaphorin 3A Increases the Regulatory Characteristics of B-Regulatory Cells
Zahava Vadasz¹, Aharon Kessel² and Elias Toubi², ¹Clinical Immunology and Allergy, Bnai-Zion Medical Center, Haifa, Israel, ²Clinical Immunology and Allergy, Bnai-Zion Medical Center, Israel
Background/Purpose: Semaphorin3A (sem3A) and neuropilin-1 (NP-1), are important regulatory molecules, previously reported by us to play role in lupus glomerulonephritis. In a recent study we…
Abstract Number: 1747 • 2012 ACR/ARHP Annual Meeting
Gemin5 Is a New Target of Autoantibodies That Are Produced in Tight Connection with Antibodies to Snrnps and Survival of Motor Neuron (SMN) Complex
Jason YF Chan¹, Yi Li¹, Angela Ceribelli², Eric S. Sobel³, Westley H. Reeves⁴, Edward K.L. Chan² and Minoru Satoh¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Most targets of autoantibodies in systemic rheumatic diseases are multiprotein-nucleic acids complex. Small nuclear ribonucleoproteins (snRNPs, Sm and U1RNP), key functional components of the…
Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting
Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Kenneth Smith¹, Jennifer Muther¹, Angie Duke¹, Emily McKee¹, Alina Lorant¹, Patrick C. Wilson² and Judith A. James³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective. However, conflicting reports regarding the impact of vaccination on autoantibody…
Abstract Number: 1749 • 2012 ACR/ARHP Annual Meeting
Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
N. Sieger¹, S.J. Fleischer¹, K. Reiter¹, H.E. Mei¹, A. Shock², G. Burmester¹, C. Daridon³ and Thomas Dorner¹, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²UCB Pharma, Slough, United Kingdom, ³Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany
Background/Purpose: CD22, a member of the sialic acid-binding immunoglobulin-like lectins (Siglec) family, is exclusively expressed on B cells at mature stage and is lost upon…
Abstract Number: 1750 • 2012 ACR/ARHP Annual Meeting
Phosphoprotein Changes Induced with Epratuzumab, an Antibody Targeting CD22 On B Cells
S. Lumb¹, N. Torbett², I. Vandrell², H. Turner², M. Page¹, P. Hales¹, A. Maloney¹, B. Vanhaesebroeck², P. Cutillas² and A. Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Activiomics Ltd., London, United Kingdom
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22 that is currently in phase III clinical trials in systemic lupus erythematosus (SLE) patients. CD22 is found…
Abstract Number: 1751 • 2012 ACR/ARHP Annual Meeting
Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren’s Syndrome
Maria Perez-Ferro¹, Sheila Recuero², Fredeswinda I. Romero¹, Cristina Serrano³, Maria J. Rodriguez-Nieto⁴, Julio Gomez-Seco², Teresa Presa², Javier R. Godo², Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute², ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Jimenez Díaz Foundation University Hospital, Madrid, Spain, ³Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Section for Autoimmune Diseases. Pneumology, Jimenez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: To assess the safety and efficacy of repeated infusions of rituximab (RTX) in patients with primary Sjögren syndrome (PSS). Methods: Patients with PSS were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].